On October 26, 2015 BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins, reported that four abstracts have been accepted for presentation at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) being held in Boston, November 5-9, 2015 (Press release, BIND Therapeutics, OCT 26, 2015, View Source [SID:1234507792]). The abstracts were published today on the AACR (Free AACR Whitepaper) website at www.AACR.org.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These posters highlight compelling data across multiple payloads and therapeutic pathways that reinforce what we believe is a powerful platform with the potential to create best-in-class therapeutics," said Andrew Hirsch, president and chief executive officer at BIND. "These data add to a growing body of evidence that further validate the ability of our Accurins to control the biodistribution of therapeutic payloads to target diseased cells while limiting exposure to healthy tissues and minimizing on-target but off-tissue toxicities. We are committed to creating innovative medicines, both through internal discovery and collaborations with leading biopharmaceutical companies, that fully leverage the benefits of our proprietary nanomedicine platform."

The posters will include preclinical and clinical pharmacokinetic data from BIND’s clinical stage Accurin compound, BIND-014, data from BIND’s preclinical stage Accurin, BIND-510, and new data from a previously unannounced feasibility study with Merck, demonstrating the potential value of an Accurin formulation of Merck’s proprietary AKT inhibitor, MK-2206.

Poster presentations at AACR (Free AACR Whitepaper) include the following:

BIND-014

1. Poster title: Cardiovascular safety profile of BIND-014 (docetaxel nanoparticles for injectable suspension) evaluated in phase 1 and 2 studies (Abstract/poster board #A161)

Date/time: November 6, 2015; 12:15 – 3:15 pm ET
Poster session category: Therapeutic Agents: Other
Location: Poster Session A; Exhibit hall C-D
2. Poster title: Evaluation of total and encapsulated drug pharmacokinetics for BIND-014 (docetaxel nanoparticles for injectable suspension) in a phase 1 study (Abstract/poster board #B144)

Date/time: November 7, 2015; 12:30 – 3:30 pm ET
Poster session category: Pharmacokinetics and Pharmacodynamics
Location: Poster Session B; Exhibit hall C-D
BIND-510

1. Poster Title: BIND-510 improves the pharmacokinetics, tolerability, tumor accumulation and tumor growth inhibition in preclinical models of cancer compared to vincristine sulfate (Abstract/poster board #C184)

Date/time: November 8, 2015; 12:30 – 3:15 pm ET
Poster session category: Therapeutic Agents: Other
Location: Poster Session C; Exhibit Hall C-D
MK-2206 Accurin

1. Poster Title: Accurins improve the pharmacokinetics, pharmacodynamics, tolerability and anti-tumor activity of the AKT inhibitor MK-2206 (Abstract/poster board #C197)

Collaborator: Merck
Date/time: November 8, 2015; 12:30 – 3:30 pm ET
Poster session category: Therapeutic Agents: Small Molecule Kinase Inhibitors
Location: Poster Session C